178 related articles for article (PubMed ID: 35592333)
1. Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma.
Zhang X; Wu Z; Hao Y; Yu T; Li X; Liang Y; Li J; Huang L; Xu Y; Li X; Xu X; Wang W; Xu G; Zhang X; Lv Q; Fang Y; Xu R; Qian W
Front Immunol; 2022; 13():888250. PubMed ID: 35592333
[TBL] [Abstract][Full Text] [Related]
2. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
[TBL] [Abstract][Full Text] [Related]
3. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3B is an enzymatic source of mutation in breast cancer.
Burns MB; Lackey L; Carpenter MA; Rathore A; Land AM; Leonard B; Refsland EW; Kotandeniya D; Tretyakova N; Nikas JB; Yee D; Temiz NA; Donohue DE; McDougle RM; Brown WL; Law EK; Harris RS
Nature; 2013 Feb; 494(7437):366-70. PubMed ID: 23389445
[TBL] [Abstract][Full Text] [Related]
5. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
[TBL] [Abstract][Full Text] [Related]
6. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
7. Polyomavirus T Antigen Induces
Starrett GJ; Serebrenik AA; Roelofs PA; McCann JL; Verhalen B; Jarvis MC; Stewart TA; Law EK; Krupp A; Jiang M; Martens JWM; Cahir-McFarland E; Span PN; Harris RS
mBio; 2019 Feb; 10(1):. PubMed ID: 30723127
[TBL] [Abstract][Full Text] [Related]
8. Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis.
Wu J; Li N; Zhu L; Zhen D; Li M; Chen H; Ye M; Wei Y; Shao G
BMC Bioinformatics; 2022 Aug; 23(1):312. PubMed ID: 35918642
[TBL] [Abstract][Full Text] [Related]
9. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
Kim H; Cho U; Hong SH; Park HS; Kim IH; An HJ; Shim BY; Kang JH
Oncol Res; 2024; 32(6):1021-1030. PubMed ID: 38827321
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
11. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Shigaki H; Kurashige J; Hiyoshi Y; Iwatsuki M; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Oki E; Watanabe M; Baba H
Med Oncol; 2016 Mar; 33(3):26. PubMed ID: 26880326
[TBL] [Abstract][Full Text] [Related]
13. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
15. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
[TBL] [Abstract][Full Text] [Related]
16. Acute expression of human APOBEC3B in mice results in RNA editing and lethality.
Alonso de la Vega A; Temiz NA; Tasakis R; Somogyi K; Salgueiro L; Zimmer E; Ramos M; Diaz-Jimenez A; Chocarro S; Fernández-Vaquero M; Stefanovska B; Reuveni E; Ben-David U; Stenzinger A; Poth T; Heikenwälder M; Papavasiliou N; Harris RS; Sotillo R
Genome Biol; 2023 Nov; 24(1):267. PubMed ID: 38001542
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
18. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
19. The role of APOBEC3B in chondrosarcoma.
Jin Z; Han YX; Han XR
Oncol Rep; 2014 Nov; 32(5):1867-72. PubMed ID: 25176183
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Schmitt C; Lucius R; Synowitz M; Held-Feindt J; Hattermann K
Oncol Rep; 2018 Nov; 40(5):2742-2749. PubMed ID: 30226610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
